Noah Berlow

Noah is a scientist, engineer, and entrepreneur focusing on the intersection of AI/ML and molecular biology to solve clinical challenges in personalized cancer care, with a focus on real-world translation and patient impact. He earned his PhD in Electrical Engineering from Texas Tech University, and has completed post-doctoral studies in bioinformatics, molecular biology, and translational drug discovery/development. He has published 35+ peer-reviewed papers in AI/ML, drug development, and personalized cancer medicine, including articles in high-impact journals such as Nature Medicine and...

MORE

Noah is a scientist, engineer, and entrepreneur focusing on the intersection of AI/ML and molecular biology to solve clinical challenges in personalized cancer care, with a focus on real-world translation and patient impact. He earned his PhD in Electrical Engineering from Texas Tech University, and has completed post-doctoral studies in bioinformatics, molecular biology, and translational drug discovery/development. He has published 35+ peer-reviewed papers in AI/ML, drug development, and personalized cancer medicine, including articles in high-impact journals such as Nature Medicine and Modern Pathology. His work has supported the development and initiation of three pediatric cancer clinical trials (NCT02717455/PBTC-047, NCT02780804/ADVL1513, NCT03838042), and he has been issued two patents for his interdisciplinary work bridging multiple fields. He has also partnered with multiple pharmaceutical companies to deliver AI/ML designed multi-omics, multi-modal biomarkers to accelerate preclinical and clinical drug development. Noah is the CTO of First Ascent Biomedical, a clinical-stage personalized medicine company focused on advancing functional precision medicine + AI/ML into large-scale clinical use to meet the needs of cancer patients around the world. Noah is co-PI on an NIH-funded R01 equivalent study supporting this personalized medicine initiative and AI/ML biomarker development (2U54MD012393), along with his co-founder and colleague Dr. Diana Azzam. Clinical results from this feasibility study were recently published by Nature Medicine and featured on Good Morning America and Fox News, and new patients are being enrolled through pan-cancer clinical trials for pediatric patients (NCT05857969) and adult patients (NCT06024603).

LESS